Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.37 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29659749 | 0.81 | IKBKB (0.47) | IKBKBAPAF1NSD2CASP3SENP8 | |
| SCHEMBL21855442 | 0.81 | IKBKB (0.54) | IKBKBAPAF1NSD2CASP3SENP8 | |
| SCHEMBL27339338 | 0.81 | IKBKB (0.47) | IKBKBAPAF1NSD2CASP3SENP8 | |
| SCHEMBL14308482 | 0.81 | IKBKB (0.47) | IKBKBAPAF1NSD2CASP3SENP8 | |
| Hydrochloric Acid SCHEMBL5008136 | 0.79 | IKBKB (0.46) | IKBKBAPAF1NSD2CASP3SENP8 | |
| SCHEMBL31726010 | 0.76 | KDM4E (0.46) | IKBKBL3MBTL1KDM4ENNMTMAPK1 | |
| SCHEMBL31208519 | 0.76 | KDM4E (0.46) | IKBKBL3MBTL1KDM4ENNMTMAPK1 | |
| SCHEMBL2696087 | 0.76 | KDM4E (0.46) | OPRM1L3MBTL1KDM4EASPHKDM8 | |
| SCHEMBL21976891 | 0.76 | IKBKB (0.43) | IKBKBAPAF1NSD2CASP3SENP8 | |
| SCHEMBL16508181 | 0.76 | IKBKB (0.43) | IKBKBAPAF1NSD2CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002275-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-06 | — | — | US | disclosed |
| EP-3556752-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| US-11198691-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-11180484-B2 | Pyrazole derivatives as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| CN-113387933-A | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-11084809-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| CN-109311847-B | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-05-11 | — | — | US | disclosed |
| EP-3760622-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2021-01-06 | — | — | EP | disclosed |
| EP-3567037-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | DRI UK LP (KY) | 2019-10-03 | — | — | US | disclosed |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| EP-3224256-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| EP-3464271-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2019-04-10 | — | — | EP | disclosed |
| CN-109311847-A | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | 卡尔维斯塔制药有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-20180319782-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | DRI UK LP (KY) | 2018-11-08 | — | — | US | disclosed |
| WO-2017207983-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-12-07 | — | — | WO | disclosed |
| EP-3224256-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | Kalvista Pharmaceuticals Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016083820-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319782-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | IKBKB 708/4885OPRM1 1894/4885APAF1 1019/4885 |
| US-11180484-B2 | Pyrazole derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | IKBKB 1226/4885OPRM1 4164/4885APAF1 381/4885 |
| US-20220002275-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | IKBKB 909/4885OPRM1 3455/4885APAF1 366/4885 |
| US-20190218205-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | IKBKB 1226/4885OPRM1 4164/4885APAF1 381/4885 |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | IKBKB 708/4885OPRM1 1894/4885APAF1 1019/4885 |
| US-11198691-B2 | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | IKBKB 579/4885OPRM1 2030/4885APAF1 1124/4885 |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | IKBKB 600/4885OPRM1 2055/4885APAF1 1075/4885 |
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | IKBKB 600/4885OPRM1 2055/4885APAF1 1075/4885 |
| US-11084809-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | IKBKB 579/4885OPRM1 2030/4885APAF1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.